ExodusPoint Capital Management’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History

ExodusPoint Capital Management’s Portfolio NGM Stock Details NGM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-107,214	Closed	-$538K	–	2211
2022 Q4	$538K	Buy	107,214 +54,542	+104%	+$342K	0.01%	1144
2022 Q3	$689K	Buy	+52,672	New	+$798K	0.01%	1255
2022 Q1	–	Sell	-20,393	Closed	-$361K	–	2783
2021 Q4	$361K	Buy	+20,393	New	+$391K	﹤0.01%	1585
2019 Q4	–	Sell	-17,400	Closed	-$241K	–	1976
2019 Q3	$241K	Buy	+17,400	New	+$261K	0.01%	1019

Other funds holding NGM

Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return

ExodusPoint Capital Management's NGM Position: Q1 2023 in Review

ExodusPoint Capital Management sold out of NGM Biopharmaceuticals, Inc. Common Stock (NGM) in Q1 2023, closing a stake of 107,214 shares — an estimated $538K sold.

ExodusPoint Capital Management first reported a position in NGM in Q3 2019 and held it in 4 quarters. The position peaked at $689K in Q3 2022. 122 funds tracked by Wall St. Rank hold NGM as of Q1 2023.

ExodusPoint Capital Management reported no remaining NGM Biopharmaceuticals, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
ExodusPoint Capital Management sold 107,214 NGM Biopharmaceuticals, Inc. Common Stock shares in Q1 2023, an estimated $538K.
ExodusPoint Capital Management first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q3 2019 and held it in 4 quarters.
ExodusPoint Capital Management's NGM Biopharmaceuticals, Inc. Common Stock position peaked at $689K in Q3 2022.
122 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q1 2023.

Based on ExodusPoint Capital Management's 13F filing for Q1 2023, filed 11 May 2023.